%0 Journal Article %A Jin-Tai Yu %A Wei Xu %A Chen-Chen Tan %A Sandrine Andrieu %A John Suckling %A Evangelos Evangelou %A An Pan %A Can Zhang %A Jianping Jia %A Lei Feng %A Ee-Heok Kua %A Yan-Jiang Wang %A Hui-Fu Wang %A Meng-Shan Tan %A Jie-Qiong Li %A Xiao-He Hou %A Yu Wan %A Lin Tan %A Vincent Mok %A Lan Tan %A Qiang Dong %A Jacques Touchon %A Serge Gauthier %A Paul S Aisen %A Bruno Vellas %T Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials %D 2020 %R 10.1136/jnnp-2019-321913 %J Journal of Neurology, Neurosurgery & Psychiatry %P jnnp-2019-321913 %X Background Evidence on preventing Alzheimer’s disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.Methods Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.Results A total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).Interpretation Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD. %U https://jnnp.bmj.com/content/jnnp/early/2020/09/02/jnnp-2019-321913.full.pdf